Since the injection of 2 or 5x106 OT-I CD8+ T cells had similar effects on tumor progression without toxicity, we decided to perform the ACT with 5x106 OT-I CD8+ T cells in order to optimize therapeutic efficacy. The gene discussed is CD8A; the disease is neoplasm.